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Abstract:
Introduction:
The study aimed to see if a community survey conducted by clinical interviewers with semi-structured psychiatric interviews shows lifetime
prevalence rates of Specific Phobia (SP) similar to those found by surveys carried out by lay interviewers and if the high level of impairment found
in SP may be confirmed.
Methods:
This is a community survey on an Italian nationwide sample randomly selected from registers of municipalities. Tools: semi-structured ANTAS
psychiatric interview derived from the SCID-DSM-IV, carried out by clinicians (psychologists or physicians); Short Form Health Survey (SF-12)
as a measure of Quality of Life (QoL). Analyses: means of the χ2 test odds ratios were adopted to test several associations regarding SP prevalence.
One-way ANOVA was used to compare different groups on attributable burden due to SP and/or other disorders in worsening QoL.
Results:
The  lifetime  prevalence  of  SP  was  2.3%.  No  difference  was  found  by  age  class.  Females  showed  more  than  twice  the  frequency  of  males
(p<0.0001). The disorders showing the closest association with SP were: social phobia (OR=17.53); general anxiety disorder (OR=11.57); anorexia
(OR=11.13) and agoraphobia (OR=10.03), but also obsessive compulsive disorders (OR=8.8), eating disorders (OR=7.2), panic disorder (OR=5.9),
post-traumatic stress disorder (OR=5.8), and major depressive disorder (OR=4.8) presented an association that achieved statistical significance.
The QoL of people with SP and at least one disorder of anxiety, mood or eating in comorbidity, measured as a score at SF12, was worse than
controls without SP (p <0.001) but that of people with SP without co-morbidity was not (p = 0.809).
Conclusion:
An epidemiological study conducted by clinical interviewers through semi-structured interviews appears to re-dimension the impact of SP, at least
from the public health perspective. Future prospective studies will better clarify the role of SP in the context of anxiety disorders.
Article History Received: January 02, 2019 Revised: January 24, 2019 Accepted: January 24, 2019
1. INTRODUCTION
Although  Specific  Phobia  (SP)  is  a  topic  not  often  ad-
dressed  by  epidemiologists  [1],  we  have  today  a  series  of
studies that place the lifetime prevalence of this disorder from
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7.4%  to  12.5%  [2  -  10].  A  milestone  was  the  World  Health
Organization’s World Mental Health Survey, an epidemiology
project  conducted  on  25  representative  population-based
samples coming from 22 countries and on 124.902 interviews
in total [10]. This large survey has found overall cross-national
lifetime SP prevalence rates of 7.4%, with higher frequencies
in  females  (9.8  vs..  4.9%)  and  in  high-  and  higher-middle-
income countries [10].
Large-scale epidemiological studies have established that
specific phobia is associated with a high level of disability and
co-morbidity with other psychiatric disorders [7]. In fact, the
National Comorbid Survey shows a considerable impairment in
people  having  a  diagnosis  of  SP,  with  34.2%  reporting
significant role impairments, even higher than in agoraphobia
(26.5%), and similar to social phobia 33.5% [11]. This shows
that  comorbid  phobias  are  more  severe  and  impairing  than
phobias without comorbidity [11].
Based  on  the  results  of  epidemiological  studies,  it  is
commonly accepted that the onset of phobia is precocious and
precedes  that  of  other  psychiatric  disorders  in  comorbidity
[10].  However,  one  of  the  few  studies  conducted  through
repeated interviews on the same cohort showed a cumulative
incidence that increased up to 50 years (age of last evaluation),
with  a  prevalence  in  the  cohort  that  increased  fivefold  from
1978  to  2008  [12].  These  results  appear  to  indicate  that  SP
onset is not restricted to youth groups. It is to be noted that the
latter research differs from others because in this survey, the
diagnoses  were  conducted  by  clinicians  through  highly
structured  interviews  and  not  by  lay  interviewers.
It  is  discussed  whether  a  methodology  adopting  lay
interviewers and rigid structured interviews can identify cases
that overlap with those that would be recognized in a clinical
setting  [13  -  15].  In  fact,  the  diagnoses  derived  from  non-
clinical interviewers might have identified a broader spectrum
of  cases  (including  sub-threshold  ones)  than  those  known in
clinical  practice.  Although  clinical  reappraisal  studies  show
sufficient concordance between structured interview-based and
clinical diagnoses of specific phobia [16], the methodology of
such reappraisal studies has raised relevant critical issues [15].
In  contrast,  the  methodology  based  on  structured
interviews  and  the  collection  of  all  symptoms  by  lay
interviewers  may  provide  information  about  prevalence  and
relevance  of  sub-syndromic  pictures  [17].  The  results  of
epidemiological  surveys  in  the  community  and  primary  care
settings adopting such a methodology have in fact clarified that
there is  an impact  in terms of disability associated with sub-
syndromic  features  in  several  disorders  [18].  Such  results
appear  to  indirectly  confirm  the  validity  of  the  approach:  if
these conditions are not clinically confirmed, they should not
be  associated  with  disability.  But  in  the  case  of  SP,  the
question  arises  as  to  whether  comorbidities  with  other
clinically relevant and severely disabling pathologies (which is
very frequent) may  lead sub-threshold  cases  of SP to  apprear
as  an association  with disability that may not be caused by the
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SP per se but by the conditions in co-morbidity. It is, therefore,
necessary  to  clarify  to  what  extent  the  levels  of  impairment
found in people with social phobia depend on this disorder, to
what  extent  they  are  the  consequence  of  comorbid  disorders
and how much they may not depend on the amplifying effect of
multiple concomitant disorders.
We consider  this  of  interest  to  study  how much  SP  may
impair the perception of Quality of Life (QoL). This concept
involves  physical  and psychological  components  of  wellness
[19].  Thus,  QoL  is  used  as  an  outcome  measure  in  chronic
diseases  and  in  those  that  require  long-term  treatments  and
which greatly impact daily life [20 - 22].
Our study, therefore, intends to see if a community survey
conducted  by  clinical  interviewers  with  semi-structured
psychiatric interviews will show lifetime prevalence rates of SP
similar  to  those  found  in  surveys  carried  out  by  lay
interviewers and if the high level of impairment found in SP is
confirmed.
2. METHODS
The  methodology  of  the  epidemiological  study  has  been
described in detail in a previously published paper [23].
2.1. Design
It is a community epidemiologic survey.
2.2. Setting
The survey was conducted in six Italian regions (Abruzzi,
Friuli-Venezia  Giulia,  Puglia,  Sicily,  Sardinia  and  Tuscany)
representative  of  the  geographical  distribution  and economic
diversity of the 20 Italian regions. In each region, one urban,
one suburban and at least one rural area were chosen.
2.3. Sample
The sample was randomly selected from the records of the
municipalities  involved.  Randomization  was  conducted  after
stratification  in  eight  cells  by  gender  and  age  groups  18-29;
30-44;  45-64;  >64.  People selected were contacted by phone
and  email.  The  interviews  were  conducted  face-to-face.
Diagnoses were conducted according to DSM-IV using a semi-
structured  interview  (ANTAS-SCID-IV)  carried  out  by
physicians  or  clinical  psychologists  [23].  The Italian  version
[24] of the Short Form Health Survey (SF-12) [25] was used to
measure the QoL.
2.4. Statistical Analysis
The  measure  of  frequency  adopted  was  lifetime  preva-
lence.
The  odds  ratio  for  DSM-IV  simple  phobia  lifetime
prevalence  by  age,  gender  and  co-morbidity  with  DSM-IV
anxiety,  mood and  eating  disorders  diagnosis  was  calculated
using one group for each table as a “pivot”.
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Table 1. Lifetime Prevalence of Specific Phobia by sex and age.
-   N (%) χ2, 1df p OR CI 95%
<30 Males 1 (0.75) ---
30-44 3 (0.79) 0.01° 0.999 0.95 0.04-10.34
45-64 6 (1.92) 0.24° 0.625 0.39 0.02-3.28
>64 2 (1.07) 0.01° 0.999 0.70 0.02-9.95
Total Males* 12 (1.18) - - - -
<30 Females 4 (2.90) --- - - -
30-44 12 (2.67) 0.02 0.884 1.01 0.29-3.72
45-64 18 (3.73) 0.21 0.643 0.77 0.21-2.47
>64 8 (3.19) 0.02 0.875 0.91 0.22-3.34
Total Females* 42 (3.17) 10.10 <0.0001 2.74 1.38-5.52
*Females vs.. Males
°with Yates’s correction





χ2* P OR CI 95%
Major Depressive Disorder 9 (16.6) 20.72 <0.0001 4.82 2.12-10.62
Obsessive Compulsive Disorder 7 (7.4) 35.68 <0.0001 8.80 3.39-21.90
Panic Disorder 9 (16.6) 27.28 <0.0001 5.89 2.57-13.01
Social Phobia 2 (3.7) 11.34 <0.0001 17.53 2.29-105.0
Agoraphobia 5 (9.2) 23.79 <0.0001 10.03 3.19-29.38
General Anxiety Disorder 10 (18.5) 64.36 <0.0001 11.57 5.09-25.71
Post-Traumatic Stress Disorder 2 (3.7) 3.22 0.07 5.81 0.89-27.60
Eating Disorders 4 (7.4) 17.16 <0.0001 7.23 2.05-22.98
Anorexia 3 (5.5) 13.79 <0.0001 11.13 2.41-44.19
Bulimia 0 (0) 0.01 0.999 --- ----
Binge Eating Disorder 1 (1.9) 0.024 0.621 4.29 0.20-33.44
*With Yates’ Correction
The  specific  frequencies  and  the  measure  of  association
were  calculated  in  people  <30  years  old  vs..  ≥30  years  old;
these were calculated concerning any anxiety, mood or eating
disorder in comorbidity as well as for comorbidity with Major
Depressive  Disorder  (MDD),  Panic  Disorder  (PD)  and
Generalized  Anxiety  Disorder  (GAD).
Statistical significance in these analyses was calculated by
means of the χ2 test odds ratios as the measure of association
and  confidence  intervals  at  95%  by  adopting  Miettinen’s
simplified  method  [26].
The numeric comparisons between the scores of SF-12 of
the different groups as well as the comparison of the value of
attributable burden derived from the SF-12 in different groups
were made by means of One-way ANOVA.
The “attributable burden” due to SP in worsening QoL was
calculated  as  the  difference  between  the  SF-12  score  in  a
sample of people without SP and the SF-12 score of the sample
with  SP.  This  control  group  of  people  without  SP  was
randomly extracted  in  a  stratified  (by  gender  and  age)  block
created for each person with SP, including all people without
SP of the same gender and ±2 years old from the database of
the research.
A similar  matching  after  block  (by  gender  and  age)  was
used to calculate the weight of the SP in worsening the QoL in
disorders  with  more  frequent  comorbidity  (MDD,  PD  and
GAD).  That  is  to  say,  a  group  of  persons  with  that  specific
disease (MDD, PD and GAD) was made, but without the SP,
from  the  database  matching  1/2  with  each  person  with  this
specific  disorder  plus  SP.  The  attributable  burden  was
calculated as the difference between the SF12 score of people
with the disorder (MDD, PD or GAD) and without SP and the
SF-12 score of people with the same disorder with SP.
2.5. Ethical Aspects
The researchers provided full information about the aims
of  the  research,  about  the  possibility  of  terminating  the
interview  and  data  protection  and  privacy  laws  to  each
interviewed  person.  The  researchers  explained  that  the  data
would  be  used  as  an  anonymous  database  to  guarantee
confidentiality.  Each  participant  signed  a  written  informed
consent  form.  Each  step  of  the  study  was  carried  out  in
accordance  with  the  Helsinki  Declaration.
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χ2* P OR CI 95%
At least one diagnosis
(anxiety, mood or eating disorder) in comorbidity
5 (50) 47.7 0.001 0.999 1.1 0.2-5.2
Major Depressive Disorder 3 (30) 13.6 0.614 0.433 2.7 0.4-17.2
Panic Disorders 1 (10) 18.2 0.025 0.876 0.5 0.1-5.0
General Anxiety Disorder 2 (20) 18.2 0.001 0.999 1.1 0.1-7.7
*With Yates’ Correction
Table 4. Comparison on Quality of Life of people with Specific Phobia and people without Specific Phobia (matching controls
½ from the community sample drawn after standardization by gender and age).




















The lifetime prevalence  of  SP in  the  overall  sample  was
2.3%. No variation of  frequencies by age class emerged,  but
females had more than twice the frequency of males (3.17 vs..
1.18%,  p  <0.0001)  Table  1.  GAD  (18.5%),  PD  (16.6%)  and
MDD  (16.6%)  were  the  most  common  in  people  with  SP
between anxiety, mood or eating disorders Table 2. However,
in  relation  to  the  frequencies  in  people  without  SP,  the
disorders showing the closest association with SP were: Social
Phobia (OR=17.53); GAD (OR=11.57); Anorexia (OR=11.13)
and Agoraphobia (OR=10.03), but also Obsessive Compulsive
Disorders  (OR=8.8),  Eating  Disorders  (OR=7.2),  Panic
Disorder  (OR=5.9),  PTSD  (OR=5.8),  Major  Depressive
Disorder  (OR=4.8)  presented  an  association  that  achieved
statistical  significance  Table  2.
People  with  SP  under  30  years  of  age  did  not  show  a
higher  frequency of  at  least  one diagnosis  (anxiety,  mood or
eating disorder)  in  comorbidity  compared to  people  over  29.
The same occurred for comorbidity with MDD, PD and GAD
Table 3.
The QoL of people with SP was worse than that of controls
without-SP matched by gender and age (p = 0.005).
The QoL of people with SP and at least one comorbid of
anxiety, mood or eating disorder measured as a score at SF12,
was worse than controls without SP (p <0.001) but of people
with  SP  without  co-morbidity,  it  was  not  worse  (p  =  0.809)
Table 4.
The attributable burden in worsening QoL due to SP with-
out  comorbidity  with  anxiety  mood  or  eating  disorders  was
found  lower  than  all  the  psychiatric  disorders  (MDD,  PD,
Eating  Disorders,  PTSD  and  OCD)  and  all  non-psychiatric
diseases (Celiac Disease, Multiple Sclerosis, Wilson’s Disease
and  Carotid  Atherosclerosis)  Table  5.  On  the  contrary,
attributable burden in worsening QoL due to SP in comorbidity
with anxiety mood or eating disorders was found similar to that
of  diseases  such  as  Wilson’s  Disease  and  Carotid  Athero-
sclerosis and to psychiatric disorders such as MDD, PD, Eating
Disorder,  PTSD  and  OCD;  it  was  found  higher  than  the
attributable burden due to Celiac Disease and Panic Disorder
and lower only than a severe and disability-associated disease
such  as  Multiple  Sclerosis  Table  5.  The  difference  between
attributable  burden  in  worsening  QoL  due  to  SP  with  com-
orbidity  with  anxiety  mood or  eating  disorders  and  the  attri-
butable burden due to SP without comorbidity was of statistical
significance.
Table 6 shows how the association of SP in co-morbidity
worsens  the  QoL  of  people  with  MDD,  PD  and  GAD  to  a
statistically non-significant extent. In fact, the average scores at
SF-12 in samples of people in the general population with these
diagnoses but without SP were higher than those of people in
our  sample  with  these  diagnoses  in  comorbidity  with  SP.
However, in none of the three cases did the comparison reach
statistical significance (MDD 33.0 ± 9.1 with SP vs. 35.5 ± 7.7
without  SP,  P=434;  PD  33.3  ±  9.8  with  SP  vs.  34.55  ±  6.2
without  SP,  P=0.700;  GAD 30.9 ± 7.  with SP vs.  32.7 ± 7.5
without SP, P=0.560).
Even the attributable burden due to SP in the three sample
of  people  with  MDD,  PD and  GAD in  comorbidity  with  SP
was found lower than that due to SP comparing people with SP
to  those  without.  Thus,  the  impact  of  SP  was  found  to  be
similar  in  people  with  MDD,  PD  and  GAD  and  in  people
without such a diagnosis.
4. DISCUSSION
An epidemiological survey conducted on a national basis
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in  Italy  with  diagnostic  methods  closer  to  clinical  practice
(clinical  interviewers  and  use  of  semi-structured  interviews)
than  those  usually  adopted  in  community  surveys  (lay
interviewers and structured interviews) has found lower (2.3%)




































































38.3±5.2 0.4±4.9 (N=28) df 1,52,53
F= 33.855
p<0.031
Specific Phobia with comorbidity 33.10±7.1 4.7±3.8 (N=26) df 1,52,53
F= 33.855
p<0.031
Table  6.  Worsening  of  Quality  of  Life  in  Specific  Phobia  in  co-morbid  disorders  in  comparison  with  disorders  without
Specific Phobia and Attributable Burden due to Specific Phobia.
- Major DepressiveDisorder
Panic Disorders Generalized Anxiety
Disorder




+SP: 6 F + 3 M
50.3±19.9
-SP: 6 F + 3 M 50.8±19.3
+SP: 9 F + 1 M
48.8±17.4
-SP: 9 F +1 M
48.08±16.7





















Attributable Burden due to SP 2.5±5.7 1.2±3.6 1.8±4.9
Attributable Burden due to SP
in people without comorbid conditions
(N=28); 0.4±4.9 (N=28); 0.4±4.9 (N=28); 0.4±4.9
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lifetime prevalence rates of SP in the community compared to
the  range  found  in  surveys  conducted  with  a  different
methodology  (7.4-12.5%).
Women  confirmed  frequencies  of  2.5  times  higher  than
males,  but  unlike  other  studies,  the  frequencies  were  found
stable in different age groups. This datum is consistent with the
result of the Zurich study [12] which showed a stable incidence
rate  in  different  ages;  it  must,  in  fact,  be  considered that  the
average duration of the disorder is not all life-long but about 20
years,  thus  a  stable  incidence  rate  (and  an  increase  in  the
cumulative rate over the years) may produce a stable lifetime
prevalence.  The  Swiss  study  is  the  only  one,  like  ours,  that
employed clinical interviewers [12].
The  study  confirms  a  close  association  of  SP  with  other
psychiatric  disorders,  in  particular,  anxiety  disorders,
especially  Social  Phobia,  Agoraphobia,  Generalized  Anxiety
Disorder  and  Panic  Disorder,  but  also  with  other  psychiatric
disorders  such  as  Anorexia  and  Major  Depressive  Disorder.
The  frequency  of  co-morbidity  with  Major  Depressive
Disorder  is  slightly  lower  than  that  reported  in  the  WMH
survey, while the association with anxiety disorders does not
appear  to  show  differences  [10].  The  frequency  of  co-
morbidities with other disorders does not differ under 30 years,
and also not for the association with at least one diagnosis of
mood, anxiety or eating disorders.
Our study did not evaluate the age of onset of SP or other
comorbid disorders. However, our data on the stability of the
prevalence  of  SP  in  the  different  age  groups,  as  well  as  the
stability of frequency of co-morbid disorders between young
and elderly people did not appear to support the hypothesis that
SP can be considered a frequent antecedent insurgent in youth
always  of  other  disorders,  especially  anxiety  disorder  that
would  appear  later.
The  impact  produced  by  the  disorder  on  the  QoL  was
found to be considerable, but on analyzing the data in detail,
this impact was found to be much higher in the forms of SP in
comorbidity with other disorders than in the forms in which SP
is present as the only psychopathological element. In this case,
the burden due to disorder in worsening the QoL is quite low.
This was also evidenced by the fact that the attributable burden
in worsening QoL due to non-comorbid SP was significantly
lower  than  that  of  all  other  compared  disorders,  both
psychiatric (MDD, PD, Eating Disorders, Agoraphobia, PTSD)
as well non-psychiatric (Multiple Sclerosis, Wilson's Disease,
Celiac Disease and Carotid Atherosclerosis). On the contrary,
the  attributable  burden  in  worsening  QoL  due  to  SP  with
comorbidity with anxiety mood or eating disorders was found
similar to that of diseases such as Wilson’s Disease and Carotid
Atherosclerosis and to psychiatric disorders such as MDD, PD,
Eating Disorder, PTSD and OCD; the burden was found higher
than the attributable burden due to Celiac Disease and Panic
Disorder and lower only than a severe and disability-associated
disease such as Multiple Sclerosis. Although in MDD, PD and
DAG, the association with SP appears to aggravate the QoL,
this  aggravation  is  not  worse  than  that  caused  by  the  same
disorders  when  not  in  comorbidity  with  SP.  These  results
appear  to  put  into  perspective  the  statement  that  SP  is
associated  with  a  substantial  impairment  [10,  11].
In  conclusion,  an  epidemiological  study  conducted  by
clinical  interviewers  through  semi-structured  interviews
appears to re-dimension the impact of a disorder such as SP, at
least from the public health perspective, owing to:
the frequency of the disorder in the community, so its[1]
impact  in  terms of  public  health  appears  to  be lower
than the estimate using lay interviewers and structured
interviews for diagnosis;
the  burden  in  worsening  the  QoL  attributable  to  the[2]
disorder is very low if it excludes the sole effect of the
forms in comorbidity. On the other hand, in co-morbid
forms, the presence of SP does not appear to cause an
amplification of  the  impairment.  In  fact,  the  level  of
the  QoL  in  MDD,  PD  and  GAD  without  SP  is  not
worse than in the same three disorders in comorbidity
with SP;
the  data  appear  to  produce  some  doubts  about  the[3]
hypothesis  that  SP  may  be  an  antecedent  of  more
serious  disorders,  useful  in  identification  in  terms  of
prevention.
The study has undoubted limitations: firstly, the age of SP
onset has not been studied and the different sub-types have not
been identified.  Furthermore,  the transversal  design makes it
possible  to  generate  hypotheses  rather  than  to  verify  them.
However,  the  same  methodology  by  adopting  the  formula
“Attributable Burden of Specific Disorder = SF-12 score in a
matched sample of people without the disorder SF-12 score of
people with diagnosis  of  this  disorder” was proposed also in
previous  studies  on  the  same  database  for  measuring  the
attributable  burden  due  to  several  disorders  in  worsening  of
QoL [27 - 33]. This method guarantees the homogeneity of the
control groups without the specific disease analyzed, used as a
comparison criterion to calculate the attributable burden due to
a given disease or disorder, thus allowing a reliable comparison
between the attributable burden of different diseases.
CONCLUSION
An  epidemiological  study  conducted  by  clinical  inter-
viewers  through  semi-structured  interviews  appears  to  re-
(Table 6) contd.....
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dimension  the  impact  of  SP  at  least  from  the  public  health
perspective.  Future prospective studies  will  better  clarify the
role of SP in the context of anxiety disorders.
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